These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1386887)

  • 1. Actions of a 5-lipoxygenase inhibitor, Sch 40120, on acute inflammatory responses.
    Smith SR; Watnick AW; Bryant RW; Billah M; Siegel MI
    J Pharmacol Exp Ther; 1992 Aug; 262(2):721-8. PubMed ID: 1386887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil.
    Jacobson PB; Jacobs RS
    J Pharmacol Exp Ther; 1992 Aug; 262(2):874-82. PubMed ID: 1323665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo immunopharmacological profile of Sch 40120.
    Smith SR; Watnick AS; Kung T; Siegel MI
    Immunopharmacol Immunotoxicol; 1993 Jan; 15(1):13-44. PubMed ID: 8450179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
    Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part I: Physiological and biochemical studies in murine inflammatory models.
    Jacobson PB; Jacobs RS
    J Pharmacol Exp Ther; 1992 Aug; 262(2):866-73. PubMed ID: 1501127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myrtucommulone from Myrtus communis exhibits potent anti-inflammatory effectiveness in vivo.
    Rossi A; Di Paola R; Mazzon E; Genovese T; Caminiti R; Bramanti P; Pergola C; Koeberle A; Werz O; Sautebin L; Cuzzocrea S
    J Pharmacol Exp Ther; 2009 Apr; 329(1):76-86. PubMed ID: 19056932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
    Rao TS; Yu SS; Djuric SW; Isakson PC
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):213-28. PubMed ID: 7812673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugs.
    Kreft AF; Failli AA; Musser JH; Kubrak DM; Banker AL; Steffan R; Demerson CA; Nelson JA; Shah US; Gray W
    Drugs Exp Clin Res; 1991; 17(8):381-7. PubMed ID: 1822830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
    Chan CC; Boyce S; Brideau C; Ford-Hutchinson AW; Gordon R; Guay D; Hill RG; Li CS; Mancini J; Penneton M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1531-7. PubMed ID: 7562530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-(2-hydroxy-4-methylphenyl)aminothiazole hydrochloride as a dual inhibitor of cyclooxygenase/lipoxygenase and a free radical scavenger. 2nd communication: anti-inflammatory activity.
    Bonne C; Latour E; Muller A; de Kozak Y; Faure JP; Malet F; Colin J; Tissot M; Giroud JP; Maghni K
    Arzneimittelforschung; 1989 Oct; 39(10):1246-50. PubMed ID: 2514693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of methotrexate on reversed passive Arthus reactions in rats.
    Yanaguimoto H; Ishizuki S; Fujihira E
    Res Commun Mol Pathol Pharmacol; 2000; 107(5-6):377-86. PubMed ID: 11589364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory effect of licofelone against various inflammatory challenges.
    Singh VP; Patil CS; Kulkarni SK
    Fundam Clin Pharmacol; 2006 Feb; 20(1):65-71. PubMed ID: 16448396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
    Müller-Peddinghaus R; Kohlsdorfer C; Theisen-Popp P; Fruchtmann R; Perzborn E; Beckermann B; Bühner K; Ahr HJ; Mohrs KH
    J Pharmacol Exp Ther; 1993 Oct; 267(1):51-7. PubMed ID: 8229782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
    Rao PN; Chen QH; Knaus EE
    J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.